Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04123379
Title Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications

hepatocellular carcinoma

lung non-small cell carcinoma

Therapies

BMS-813160 + Nivolumab

Nivolumab

BMS-986253 + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.